Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Carisbamate (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors SK Life Science
- 02 Apr 2024 Status changed from active, no longer recruiting to completed.
- 18 May 2023 Planned End Date changed from 31 Dec 2022 to 31 Jul 2023.
- 16 Dec 2022 Planned primary completion date changed from 31 Oct 2022 to 31 Dec 2022.